Review
Infectious Diseases
Chienhsiu Huang, Ihung Chen, Lichen Lin
Summary: Combination therapy with daptomycin plus ceftaroline may reduce mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia. The combination therapy group had similar in-hospital mortality, duration of bacteremia, and adverse event rate compared to the monotherapy group, but had lower bacteremia recurrence.
Article
Infectious Diseases
Stephen H. Zinner, Kamilla N. Alieva, Maria Golikova, Elena N. Strukova, Yury A. Portnoy, Alexander A. Firsov
Summary: This study explored the restriction of Staphylococcus aureus resistance to linezolid/daptomycin combinations, showing that the combination therapy prevented the enrichment of linezolid-resistant mutants and restricted the daptomycin-resistant mutants. The anti-mutant effects of the combinations were attributed to the lengthening of time above MPC of both antibiotics, which suggests that T->MPC is a reliable predictor of the efficacy of antibiotic combinations against resistant mutants in in vitro dynamic models.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Review
Infectious Diseases
Hitoshi Kawasuji, Kentaro Nagaoka, Yasuhiro Tsuji, Kou Kimoto, Yusuke Takegoshi, Makito Kaneda, Yushi Murai, Haruka Karaushi, Kotaro Mitsutake, Yoshihiro Yamamoto
Summary: In a systematic review and meta-analysis, the effectiveness and safety of linezolid (LZD) compared to vancomycin (VCM), teicoplanin (TEIC), or daptomycin (DAP) in treating methicillin-resistant Staphylococcus aureus (MRSA) bacteremia were evaluated. The study found that LZD had comparable effectiveness as VCM, TEIC, or DAP and similar rates of adverse events. LZD could be a potential first-line drug against MRSA bacteremia.
Review
Medicine, General & Internal
Xiao-Bing Hong, Ze-Lin Yu, Hong-Bo Fu, Ze-Hong Cai, Jie Chen
Summary: This case study highlights the efficacy of daptomycin combined with linezolid in treating bacteremia caused by MRSA with pulmonary complications. The patient showed significant improvement after switching to dual-drug treatment, with abscess culture turning negative for MRSA after 10 days. The use of innovative antibacterial drugs is crucial in the face of increasing drug resistance among gram-positive cocci.
WORLD JOURNAL OF CLINICAL CASES
(2022)
Article
Infectious Diseases
Jasmina Al Janabi, Staffan Tevell, Raphael Niklaus Sieber, Marc Stegger, Bo Soderquist
Summary: This study investigated the susceptibility of Staphylococcus epidermidis strains from prosthetic joint infections to dalbavancin and the genomic variation in strains with reduced susceptibility. The results suggest that exposure to dalbavancin may lead to reduced susceptibility through selection of pre-existing subpopulations, epigenetic changes, or spontaneous mutations during antibiotic exposure. Therefore, source control and adequate antibiotic concentrations are important to prevent emerging reduced susceptibility during dalbavancin treatment.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Yanlei Xu, Bingjie Wang, Huilin Zhao, Xinyi Wang, Lulin Rao, Wenxiu Ai, Jingyi Yu, Yinjuan Guo, Xiaocui Wu, Fangyou Yu, Shuying Chen
Summary: The study found that all MRSA isolates remained sensitive to vancomycin, teicoplanin, linezolid and daptomycin, but an increase in MIC50 and MIC90 was observed for linezolid.
INFECTION AND DRUG RESISTANCE
(2021)
Article
Immunology
Matthew P. Cheng, Alexander Lawandi, Guillaume Butler-Laporte, Samuel De L'Etoile-Morel, Katryn Paquette, Todd C. Lee
Summary: The study aimed to determine the efficacy of synergistic treatment with daptomycin when given with either cefazolin or cloxacillin for the treatment of MSSA BSI. Results showed that adjunctive daptomycin therapy did not shorten the duration of bacteremia when added to standard-of-care treatment for MSSA BSIs, and should not be routinely considered.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Hideo Kato, Mao Hagihara, Nobuhiro Asai, Yuichi Shibata, Yusuke Koizumi, Yuka Yamagishi, Hiroshige Mikamo
Summary: This study found through a meta-analysis of RCTs and CSs that LZD has significantly higher clinical cure and microbiological eradication rates compared to VCM in the treatment of proven MRSA pneumonia. However, there was no significant difference in mortality and adverse events between VCM and LZD.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2021)
Article
Microbiology
Robby Markwart, Niklas Willrich, Tim Eckmanns, Guido Werner, Olaniyi Ayobami
Summary: The study found that resistance to linezolid and daptomycin in VREF and MRSA between 2014 and 2018 was relatively low, indicating the continued effectiveness of these last-resort antibiotics in Europe. However, efforts to monitor and contain antimicrobial resistance should be strengthened at regional and national levels.
FRONTIERS IN MICROBIOLOGY
(2021)
Review
Pharmacology & Pharmacy
Masaru Samura, Yuki Kitahiro, Sho Tashiro, Hiromu Moriyama, Yuna Hamamura, Isamu Takahata, Rina Kawabe, Yuki Enoki, Kazuaki Taguchi, Yoshio Takesue, Kazuaki Matsumoto
Summary: This systematic review and meta-analysis compares the efficacy of daptomycin and vancomycin in adult patients with bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) with a vancomycin minimum inhibitory concentration (MIC) > 1 mu g/mL. The results show that daptomycin treatment is associated with lower mortality and higher treatment success compared to vancomycin, regardless of the vancomycin MIC test method used. Daptomycin should be considered as a treatment option for MRSA bacteremia with a vancomycin MIC > 1 mu g/mL, especially in patients with intermediate- and high-risk bacteremia sources.
Article
Immunology
Marin L. Schweizer, Kelly Richardson, Mary S. Vaughan Sarrazin, Michihiko Goto, Daniel J. Livorsi, Rajeshwari Nair, Bruce Alexander, Brice F. Beck, Michael P. Jones, Mireia Puig-Asensio, Daniel Suh, Madeline Ohl, Eli N. Perencevich
Summary: Among patients with methicillin-resistant Staphylococcus aureus bloodstream infections, switching to daptomycin is associated with lower 30-day mortality, especially when done within 3 days of initial vancomycin receipt. However, switching to daptomycin at any time during the first hospitalization did not significantly affect 30-day mortality.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Microbiology
Ya-Xin Fan, Meng-Ting Chen, Nan-Yang Li, Xiao-Fen Liu, Min-Jie Yang, Yuan-Cheng Chen, Xiao-Yu Liang, Ju-Fang Wu, Bei-Ning Guo, Si-Chao Song, Yong-Qiang Zhu, Feng-Ying Zhang, Jing-Qing Hang, Sheng-Bin Wu, Bo Shen, Hua-Yin Li, Qin Wang, Xu-Ming Luo, Qing-Ge Chen, Hui-Fang Zhang, Rui-Lan Wang, Li-Hua Shen, Feng-Ming Fu, Xiao-Lian Song, Jing Zhang
Summary: This study analyzed risk factors for vancomycin failure in patients with MRSA pneumonia and found that factors such as vancomycin dosage, peak concentration, and specific genes were associated with clinical improvement and eradication of the bacteria. ST5 strains were identified as potential predictors of bacterial persistence and were associated with higher levels of resistance and virulence genes.
MICROBIOLOGY SPECTRUM
(2022)
Article
Multidisciplinary Sciences
Elizabeth V. K. Ledger, Stephane Mesnage, Andrew M. Edwards
Summary: The host environment can significantly impact the efficacy of antimicrobial therapies through diverse mechanisms, including inducing changes in the composition of bacterial membrane and cell wall. Understanding the influence of the host environment on treatment outcomes can help develop combination therapies to mitigate antibiotic resistance.
NATURE COMMUNICATIONS
(2022)
Article
Microbiology
Monika Kumaraswamy, Kamilla Wiull, Bishnu Joshi, George Sakoulas, Armin Kousha, Gustav Vaaje-Kolstad, Mona Johannessen, Kristin Hegstad, Victor Nizet, Fatemeh Askarian
Summary: This study revealed that MRSA-derived MVs are capable of reducing the pathogen's susceptibility to VAN, thereby increasing its resistance to treatment, particularly in interactions with human neutrophils. Additionally, the elevated expression of proteins associated with antibiotic resistance in MVs may further impact MRSA's resistance.
Article
Infectious Diseases
Louis D. Saravolatz, Joan Pawlak
Summary: Fosfomycin exhibited excellent activity against MRSA, including isolates with reduced susceptibility or resistance to other anti-MRSA drugs. Synergy was observed when fosfomycin was combined with linezolid or daptomycin. These combinations may have potential clinical utility in treating serious infections caused by MRSA.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)